Dr Bauche holds a PhD in molecular biology and biochemistry and a MagistÃ¨re in human genetics and biostatistics (Paris VII). During her previous experience with Institut Pasteur (VACACT european project) and Ecole Normale SupÃ©rieure (CLINIGENE network of excellence), she led scientific projects and international collaborations in the fields of therapeutic proteins and viral vector engineering. Since 2007, she leads Theravectys' research team to implement a technological platform for lentivectors production and to develop lentivector-based vaccine candidates. Hence she managed the design and the production of Theravectys' first candidate, an anti-HIV therapeutic vaccine which will enter clinical phase I/II in October 2012 . She was also in charge of the design and management of the preclinical studies to evaluate the vaccine candidate safety, and took part in the interactions with the European and French regulatory authorities for the application for clinical trial authorization
Blogged on behalf of Milana Shapira and Sophia Doll
Dr. CÃ©cile Bauche presented the design and development of a new lentiviral based anti-HIV therapeutic vaccine. The later is based on a DNA flap lentivector. Results of preclinical phases were very promising. Not only did experiments for prophylactic SIV vaccines in monkeys show an induction of a strong T cell response against the viral Gag antigen protein, but experiments in mice also have allowed the authorisation for clinical trials in humans. Patients participating at clinical trials will stop the conventional HAART treatment, regardless of the injected dose of the lentiviral based anti-HIV vaccine. A strong cellular response against HIV and the survival of patients with no conventional HIV treatment is expected. We look forward to positive clinical results from Theravectys…
Tell us what you think about this exciting innovation below!
The presentations from the event will be made available from the 1st November.